We are live on ! Find out more
CINC

CinCor Pharma, Inc. Common Stock
CINC

Delisted

CINC was delisted on the 23rd of February, 2023.

Back to rankings

102 hedge funds and large institutions have $461M invested in CinCor Pharma, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 34 increasing their positions, 19 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

84% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 19

79% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 19

19% more funds holding

Funds holding: 86 → 102 (+16)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

62% less capital invested

Capital invested by funds: $1.21B → $461M (-$752M)

68% less call options, than puts

Call options by funds: $2.68M | Put options by funds: $8.47M

Holders
102
Holders Change
+16
Holders Change %
+18.6%
% of All Funds
1.64%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.06%
New
35
Increased
34
Reduced
19
Closed
19
Calls
$2.68M
Puts
$8.47M
Net Calls
-$5.79M
Net Calls Change
-$2.72M

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$37.9M
2
GPP
Great Point Partners
Connecticut
+$17.1M
3
BlackRock
BlackRock
New York
+$11.1M
4
SFM
Sphera Funds Management
Israel
+$9.79M
5
SCM
Silverarc Capital Management
Massachusetts
+$9.42M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$43.1M
2
VP
venBio Partners
California
-$35.2M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$24.7M
4
PA
Perceptive Advisors
New York
-$17.4M
5
SAM
Sectoral Asset Management
Quebec, Canada
-$6.42M
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
101
BVF Inc
California
– -$43.1M -1,312,443 Closed
SAM
102
Sectoral Asset Management
Quebec, Canada
– -$6.42M -195,534 Closed
Ensign Peak Advisors
103
Ensign Peak Advisors
Utah
– -$2.58M -78,480 Closed
EI
104
EAM Investors
California
– -$2.1M -63,839 Closed
IHAM
105
Integral Health Asset Management
New York
– -$1.64M -50,000 Closed
IC
106
Ikarian Capital
Texas
– -$1.48M -45,100 Closed
EGI
107
EAM Global Investors
California
– -$1.4M -42,629 Closed
MIM
108
Monashee Investment Management
Massachusetts
– -$985K -30,000 Closed
SGM
109
Seven Grand Managers
New York
– -$656K -20,000 Closed
BFM
110
Boothbay Fund Management
New York
– -$450K -13,718 Closed
SEI Investments
111
SEI Investments
Pennsylvania
– -$389K -11,850 Closed
BNP Paribas Financial Markets
112
BNP Paribas Financial Markets
France
– -$389K -11,849 Closed
Walleye Trading
113
Walleye Trading
New York
– -$270K -8,226 Closed
VOYA Investment Management
114
VOYA Investment Management
Georgia
– -$252K -7,690 Closed
Renaissance Technologies
115
Renaissance Technologies
New York
– -$230K -7,000 Closed
State Board of Administration of Florida Retirement System
116
State Board of Administration of Florida Retirement System
Florida
– -$230K -7,000 Closed
Invesco
117
Invesco
Georgia
– -$227K -6,907 Closed
Wells Fargo
118
Wells Fargo
California
– -$2K -46 Closed
Nisa Investment Advisors
119
Nisa Investment Advisors
Missouri
– -$286 -12 -75%
C
120
Covestor
United Kingdom
– +$95 +4 New
1 2 3 4
5

CINC Hedge Fund Activity: Q4 2022 in Review

102 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in CinCor Pharma, Inc. Common Stock (CINC) for Q4 2022, worth a combined $461M — down 62% from $1.21B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new CINC positions and 19 closed out — a net gain of 16 holders — while 34 added to existing stakes and 19 trimmed.

The largest buyer was OrbiMed, adding an estimated $37.9M. The largest seller was BVF Inc, exiting entirely with an estimated $43.1M sold.

  • 102 institutional investors held CinCor Pharma, Inc. Common Stock (CINC) as of Q4 2022, up from 86 in Q3 2022.
  • Funds reported $461M of CinCor Pharma, Inc. Common Stock stock for Q4 2022, down 62% quarter-over-quarter.
  • 35 funds opened new CinCor Pharma, Inc. Common Stock positions in Q4 2022 and 19 closed out, a net change of +16 holders.
  • The largest CinCor Pharma, Inc. Common Stock buyer in Q4 2022 was OrbiMed, an estimated $37.9M added.
  • The largest CinCor Pharma, Inc. Common Stock seller in Q4 2022 was BVF Inc, an estimated $43.1M sold.

Based on aggregated 13F filings for Q4 2022.